MCK Stock Gains 4% in 3 Weeks: Should You Buy, Hold or Sell?

McKesson (MCK) has started 2025 on a positive note, with the stock climbing 4% so far in January as investors remain optimistic about the company’s performance in 2025. MCK’s growth this year will be driven by its strategic focus on oncology and biopharma services, supported by the expansion of The US Oncology Network and the launch of InspiroGene for cell and gene therapies.Rising demand for specialty pharmaceuticals, including GLP-1 medications, should further improve revenues. Investments in Prescription ...